Literature DB >> 18690103

Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Christie D Fowler1, Michael A Arends, Paul J Kenny.   

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) can regulate the activity of many neurotransmitter pathways throughout the central nervous system and are considered to be important modulators of cognition and emotion. nAChRs are also the primary site of action in the brain for nicotine, the major addictive component of tobacco smoke. nAChRs consist of five membrane-spanning subunits (alpha and beta isoforms) that can associate in various combinations to form functional nAChR ion channels. Owing to a dearth of nAChR subtype-selective ligands, the precise subunit composition of the nAChRs that regulate the rewarding effects of nicotine and the development of nicotine dependence are unknown. The advent of mice with genetic nAChR subunit modifications, however, has provided a useful experimental approach to assess the contribution of individual subunits in vivo. Here, we review data generated from nAChR subunit knockout and genetically modified mice supporting a role for discrete nAChR subunits in nicotine reinforcement and dependence processes. Importantly, the rates of tobacco dependence are far higher in patients suffering from comorbid psychiatric illnesses compared with the general population, which may at least partly reflect disease-associated alterations in nAChR signaling. An understanding of the role of nAChRs in psychiatric disorders associated with high rates of tobacco addiction, therefore, may reveal novel insights into mechanisms of nicotine dependence. Thus, we also briefly review data generated from genetically modified mice to support a role for discrete nAChR subunits in anxiety disorders, depression, and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690103      PMCID: PMC2669417          DOI: 10.1097/FBP.0b013e32830c360e

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  346 in total

1.  Serotonergic reinnervation reverses lesion-induced decreases in PSA-NCAM labeling and proliferation of hippocampal cells in adult rats.

Authors:  J M Brezun; A Daszuta
Journal:  Hippocampus       Date:  2000       Impact factor: 3.899

Review 2.  Pharmacologic approaches to smoking cessation.

Authors:  D P Sachs; S J Leischow
Journal:  Clin Chest Med       Date:  1991-12       Impact factor: 2.878

3.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

4.  Nicotinic regulation of calcium/calmodulin-dependent protein kinase II activation in the spinal cord.

Authors:  M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2006-10-13       Impact factor: 4.030

5.  Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers.

Authors:  J Foulds; J A Stapleton; N Bell; J Swettenham; M J Jarvis; M A Russell
Journal:  Drug Alcohol Depend       Date:  1997-03-14       Impact factor: 4.492

Review 6.  Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships.

Authors:  Sandra Baker Morissette; Matthew T Tull; Suzy Bird Gulliver; Barbara Wolfsdorf Kamholz; Rose T Zimering
Journal:  Psychol Bull       Date:  2007-03       Impact factor: 17.737

7.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

Review 8.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

9.  Decreased anxiety-like behavior in beta3 nicotinic receptor subunit knockout mice.

Authors:  T K Booker; Christopher M Butt; Jeanne M Wehner; Stephen F Heinemann; Allan C Collins
Journal:  Pharmacol Biochem Behav       Date:  2007-04-21       Impact factor: 3.533

10.  Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain. Evidence for nicotine induced increases of dopamine turnover in various telencephalic dopamine nerve terminal systems.

Authors:  K Andersson; K Fuxe; L F Agnati; P Eneroth
Journal:  Med Biol       Date:  1981-06
View more
  48 in total

1.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  Rapid smoking may not be aversive in schizophrenia.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2012-02-07       Impact factor: 4.244

3.  Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  Nicotine Tob Res       Date:  2010-11-22       Impact factor: 4.244

4.  Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

Authors:  Maryka Quik; Carla Campos; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

Review 5.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

6.  An Adolescent Substance Prevention Model Blocks the Effect of CHRNA5 Genotype on Smoking During High School.

Authors:  David J Vandenbergh; Gabriel L Schlomer; H Harrington Cleveland; Alisa E Schink; Kerry L Hair; Mark E Feinberg; Jenae M Neiderhiser; Mark T Greenberg; Richard L Spoth; Cleve Redmond
Journal:  Nicotine Tob Res       Date:  2015-05-04       Impact factor: 4.244

7.  Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.

Authors:  Andrew C Harris; Laura Tally; Clare E Schmidt; Peter Muelken; Irina Stepanov; Subhrakanti Saha; Rachel Isaksson Vogel; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2014-12-23       Impact factor: 4.492

8.  Discovery of Novel α4β2 Neuronal Nicotinic Receptor Modulators through Structure-Based Virtual Screening.

Authors:  Kiran V Mahasenan; Ryan E Pavlovicz; Brandon J Henderson; Tatiana F González-Cestari; Bitna Yi; Dennis B McKay; Chenglong Li
Journal:  ACS Med Chem Lett       Date:  2011-09-18       Impact factor: 4.345

9.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

10.  Nicotine-induced enhancement of responding for conditioned reinforcement in rats: role of prior nicotine exposure and α4β2 nicotinic receptors.

Authors:  Elizabeth Glenn Guy; Paul J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2012-08-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.